Table 3.
Maximum stimulation (Emax) and potency (pEC50) values for methanandamide (CB1 agonist) and CB65 (CB2 agonist) inducing [35S]GTPγS binding in microvessels of the hippocampus and temporal neocortex of non-epileptic autopsies and patients with DR-MTLE.
| Receptor, brain area, and group | Emax fmol/mg prot | p < | pEC50 | p < |
|---|---|---|---|---|
| CB1 hippocampus autopsies |
146 ± 11 | 0.0008* | −6.65 ± 0.34 | 0.8687 |
| CB1 hippocampus DR-MTLE |
513 ± 93 | −6.52 ± 0.7 | ||
| CB2 hippocampus autopsies |
108 ± 10 | 0.0001* | −8.1 ± 0.37 | 0.035* |
| CB2 hippocampus DR-MTLE |
384 ± 49 | −6.7 ± 0.49 | ||
| CB1 neocortex autopsies |
333 ± 45 | 0.006* | −6.23 ± 0.46 | 0.9459 |
| CB1 neocortex DR-MTLE |
676 ± 105 | −6.18 ± 0.5 | ||
| CB2 neocortex autopsies |
290.9 ± 29 | 0.2639 | −7.86 ± 0.39 | 0.0002* |
| CB2 neocortex DR-MTLE |
339.7 ± 30 | −5.7 ± 0.26 |
Emax, maximum stimulation; pEC50, −log of half-effective concentration (potency); DR-MTLE, drug-resistant mesial temporal lobe epilepsy.
*
p < 0.05.